Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.


  • Development of a manuscript from an existing report detailing an analysis already performed using an existing economic model in dyslipidemia


  • Payer value proposition in dyspepsia
  • Interviews in dyspepsia
  • Development of a briefing packet for a FDA Type C meeting for a primary endpoint in functional dyspepsia
  • Linguistic validation of the Severity of Dyspepsia Assessment (SODA) and Pain Treatment Satisfaction Scale (PTSS) questionnaires into UK English
  • Development of a PRO to assess the symptoms of functional dyspepsia for the purposes of labelling
  • Quantitative research in functional dyspepsia

Ear infections and acute otitis media

  • Diary of a caregiver validation for ear infection using the standard methodology
  • Training and manuscripts on the acute otitis media caregiver diary
  • Quality of life impact of otitis media and associated productivity loss in Malaysia and South Korea

Economic models

We have extensive experience in modelling across a wide range of indications – our model experience includes budget impact models, cost effectiveness models, scenario models, cost calculator models, value-based pricing models, cost offset models, and cost utility models. Our experience is vast in this area and models have been developed for a large number of countries and with adaptations for different markets. We have developed models and model adaptations throughout Europe (including the EU5, eastern Europe and Scandinavia), on a Global scale, and for the US, Canada, Japan, Australia, Mexico and Brazil.

  • Acromegaly
  • Acute bacterial skin and skin structure infections (ABSSSI)
  • Allergies
  • Alzheimer’s disease
  • Anaemia
  • Anaesthesiology
  • Ankylosing spondylitis
  • Asthma
  • Benign prostatic hyperplasia
  • Bladder cancer
  • Breakthrough cancer pain
  • Breast cancer
  • Cardiometabolic risk
  • Chronic obstructive pulmonary disease (COPD)
  • Clostridium difficile infections
  • Colonoscopy
  • Colorectal cancer
  • Crohn’s disease
  • Diabetes (type 1 and 2)
  • Diabetic macular edema
  • Dyslipidaemia
  • Epilepsy
  • Esophogeal cancer
  • Gastric cancer
  • Head and neck cancer
  • Hepatitis C
  • HIV
  • Hormone replacement therapy
  • HPV
  • Human cord graft
  • Hypertension
  • Infection prevention
  • Infertility
  • Inflammatory bowel disease
  • Influenza
  • Leukaemia
  • Lung cancer (small cell and non-small cell)
  • Lymphomas
  • Melanoma
  • Mesothelioma
  • Multiple myeloma
  • Neuroendocrine tumours
  • Neuromuscular block
  • Osteoarthritis
  • Ovarian cancer
  • Pain
  • Parkinson’s disease
  • Phenylketonuria
  • Pneumococcal disease
  • Post-herpetic neuralgia
  • Psoriasis
  • Psoriatic arthritis
  • Renal cell carcinoma
  • Rheumatoid arthritis
  • Surgery and post-operative pain


  • Literature review to identify the chronic hand eczema population in the US
  • Regulatory support in chronic hand eczema
  • Development of a manuscript to communicate the patient experience of chronic hand eczema
  • Two abstracts to communicate the development of a conceptual model in chronic hand eczema


  • General consultancy on economics, quality of life and reimbursement in lung volume reduction surgery in emphysema


  • Validation of ePRO endpoints and a regulatory dossier to support claims in endometriosis
  • Qualitative research in Europe and validation of ePRO endpoints to support product labelling claims in endometriosis
  • Development and validation of ePRO endpoints for use in endometriosis
  • Psychometric validation and communications for newly developed PROs in endometriosis
  • PRO instrument development in endometriosis
  • Manuscript on PRO development and validation in endometriosis
  • Endpoint validation and finalisation in endometriosis
  • Review of a revision of a psychometric validation report on endometriosis and in-person attendance at FDA meeting
  • Endometriosis symptom diary and impact scale communications strategy
  • Exploration of instrument scoring (following EMA CHMP advice), psychometric evaluation using data from clinical studies and development of instrument user manuals in endometriosis
  • Consultancy services for linguistic validation of an endometriosis symptom diary and endometriosis impact scale
  • Endpoint review and regulatory support regarding the suitability of the Biberoglu & Behrman Scale (B&B) and Endometriosis Health Profile-30 (EHP-30) for supporting US product labelling claims in endometriosis
  • FDA PRO dossier updates and the development of Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS) user manuals
  • Review of a briefing book concerning a compound in development for the treatment of pain and other symptoms arising from endometriosis
  • Face and content validity of a new measure to assess symptoms associated with endometriosis
  • Development and face and content validation of a diary to assess symptoms associated with endometriosis
  • Development of disease-specific modules for endometriosis

Endpoint reviews with an FDA component

  • Diabetic foot ulcers
  • Diabetic macular oedema
  • Diarrhoea-predominant irritable bowel syndrome
  • Dysmenorrhea
  • Epilepsy
  • Epoietin alfa in chronic kidney disease
  • Functional digestive disorders (post-prandial distress syndrome)
  • Hereditary angioedema
  • Hypogonadism
  • Major depressive disorder
  • Pain
  • Pulmonary arterial hypertension
  • Retinal vein occlusion
  • Rheumatoid arthritis

Eosinophilic esophagitis

  • Development and validation of a PRO measure in paediatric patients with eosinophilic esophagitis
  • Qualitative interviews to develop a symptom measure in adult patients with eosinophilic esophagitis
  • Re-analysis of qualitative data and cognitive debriefing interviews to create a symptom measure in esonophilic esophagitis
  • Analysis of a field trial on eosinophilic esophagitis
  • Cognitive debriefing and modification of the Eosinophilic Esophagitis Activity Index (EEsAI)
  • Modification of the Eosinophilic Esophagitis Activity Index (EEsAI)